Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

3.490 -0.340 (-8.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Jaguar Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Via ACCESS Newswire
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series
Via ACCESS Newswire
Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer
Via ACCESS Newswire
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series
Via ACCESS Newswire
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
Jaguar Health, Inc. Announces Reverse Stock Split
Via ACCESS Newswire
First Patient Randomized in Jaguar Health’s Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)
Via ACCESS Newswire
Jaguar Health Reports First Quarter 2025 Financials
Via ACCESS Newswire
Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates
Via ACCESS Newswire
Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
Via ACCESS Newswire
Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts
Via ACCESS Newswire
Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease
Via ACCESS Newswire
REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Via ACCESS Newswire
Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast
Via ACCESS Newswire
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress
Via ACCESS Newswire
Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting
Via ACCESS Newswire
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product
Via ACCESS Newswire
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESS Newswire
Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023
Via ACCESS Newswire
83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey
Via ACCESS Newswire
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
Via ACCESS Newswire
Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts
Via ACCESS Newswire
Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders
Via ACCESS Newswire
Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value
Via ACCESS Newswire
Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Via ACCESS Newswire
Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
Via ACCESS Newswire
Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
Via ACCESS Newswire
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback